A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of D4064A Administered Intravenously to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer After a Platinum-Containing Regimen
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence and nature of dose-limiting toxicities (DLTs)
Length of study
Scott Holden, M.D.
United States: Food and Drug Administration
|Investigational Site||New York, New York 10032|
|Investigational Site||Nashville, Tennessee 37203|